6-(4-氯苯氧基)己烷-1-胺 | 200484-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 6-(4-氯苯氧基)己烷-1-胺
• 英文名称: 6-(4-chlorophenoxy)hexylamine
• 英文别名: 6-(4-chlorophenoxy)hexyl-1-amine；6-p-chlorophenoxyhexylamine；6-(4-chlorophenoxy)hexan-1-amine
• CAS: 200484-41-9
• 化学式: C₁₂H₁₈ClNO
• mdl: MFCD02684208
• 分子量: 227.734
• InChiKey: LTUFMALBFAADRT-UHFFFAOYSA-N

物化性质

• 沸点：
  336.8±22.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯苯并咪唑 、 6-(4-氯苯氧基)己烷-1-胺 以 异戊醇 为溶剂， 反应 16.0h， 以85%的产率得到(1H-Benzoimidazol-2-yl)-[6-(4-chloro-phenoxy)-hexyl]-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series

  摘要：

  A novel series of non-imidazole H-3-receptor antagonists was developed, by chemical modification of a potent lead H-3-antagonist composed by an imidazole ring connected through an alkyl spacer to a 2-aminobenzimidazole moiety (e.g., 2-[[3-[4(5)-imidazolyl]propyl]amino]benzimidazole), previously reported by our research group. We investigated whether the removal of the imidazole ring could allow retaining high affinity for the H-3-receptor, thanks to the interactions undertaken by the 2-aminobenzimidazole moiety at the binding site. The imidazole ring of the lead was replaced by a basic piperidine or by a lipophilic p-chlorophenoxy substituent, modulating the spacer length from three to eight methylene groups; moreover, the substituents were moved to the 5(6) position of the benzimidazole nucleus. Within both the 2-alkylaminobenzimidazole series and the 5(6)-alkoxy-2-amino-benzimidazole one, the greatest H-3-receptor affinity was obtained for the piperidine-substituted compounds, while the presence of the p-chlorophenoxy group resulted in a drop in affinity. The optimal chain length was different in the two series. Even if the new compounds did not reach the high receptor affinity shown by the imidazole-containing lead compound, it was possible to get good H-3-antagonist potencies with 2-aminobenzimidazoles having a tertiary amino group at appropriate distance. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.09.063
• 作为产物：
  描述：

  6-(4-氯苯氧基)己腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以49%的产率得到6-(4-氯苯氧基)己烷-1-胺
  参考文献：
  名称：

  Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series

  摘要：

  A novel series of non-imidazole H-3-receptor antagonists was developed, by chemical modification of a potent lead H-3-antagonist composed by an imidazole ring connected through an alkyl spacer to a 2-aminobenzimidazole moiety (e.g., 2-[[3-[4(5)-imidazolyl]propyl]amino]benzimidazole), previously reported by our research group. We investigated whether the removal of the imidazole ring could allow retaining high affinity for the H-3-receptor, thanks to the interactions undertaken by the 2-aminobenzimidazole moiety at the binding site. The imidazole ring of the lead was replaced by a basic piperidine or by a lipophilic p-chlorophenoxy substituent, modulating the spacer length from three to eight methylene groups; moreover, the substituents were moved to the 5(6) position of the benzimidazole nucleus. Within both the 2-alkylaminobenzimidazole series and the 5(6)-alkoxy-2-amino-benzimidazole one, the greatest H-3-receptor affinity was obtained for the piperidine-substituted compounds, while the presence of the p-chlorophenoxy group resulted in a drop in affinity. The optimal chain length was different in the two series. Even if the new compounds did not reach the high receptor affinity shown by the imidazole-containing lead compound, it was possible to get good H-3-antagonist potencies with 2-aminobenzimidazoles having a tertiary amino group at appropriate distance. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.09.063
• 作为试剂：
  描述：

  S-methyl-N-cyano-N'-4-pyridylisothiourea 、 6-(4-氯苯氧基)己烷-1-胺 在 6-(4-氯苯氧基)己烷-1-胺 作用下， 以89的产率得到N-[6-(4-氯苯氧基)己基]-N'-氰基-N''-4-吡啶基胍
  参考文献：
  名称：

  Bioorg. Med. Chem. Lett. 1997, 7, 3095-3100

  摘要：

  DOI：

文献信息

• PYRIDYL CYANOGUANIDINE DERIVATIVES
  申请人：Zhang Hesheng

  公开号：US20120309797A1

  公开（公告）日：2012-12-06

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R 1 , R 2 and n are described in description.

  公式（I）的化合物或其药用盐的使用，以及用于治疗癌症的方法已被披露，其中，X、Y、R1、R2和n的定义在描述中描述。
• [EN] PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)<br/>[FR] DÉRIVÉS DE PIPÉRIDINE ET COMPOSITIONS POUR L'INHIBITION DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NAMPT)
  申请人：FORMA TM LLC

  公开号：WO2012154194A1

  公开（公告）日：2012-11-15

  The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I)

  本发明涉及用于抑制NAMPT的化合物和组合物，它们的合成、应用和解毒剂。本发明的一种示例化合物如下所示：式（I）
• NAMPT AND ROCK INHIBITORS
  申请人：Curtin Michael L.

  公开号：US20120122842A1

  公开（公告）日：2012-05-17

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

  公开了一种抑制NAMPT活性的化合物，包含该化合物的组合物和治疗NAMPT表达疾病的方法。公开了一种抑制ROCK活性的化合物，包含该化合物的组合物和治疗ROCK表达疾病的方法。
• PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
  申请人：Bair Kenneth W.

  公开号：US20140248240A1

  公开（公告）日：2014-09-04

  The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I)

  本发明涉及用于抑制NAMPT的化合物和组合物，它们的合成、应用和解毒剂。本发明的一个说明性化合物如下所示：公式（I）
• Nampt and Rock Inhibitors
  申请人：AbbVie Inc.

  公开号：US20160031880A1

  公开（公告）日：2016-02-04

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.

  本发明涉及抑制NAMPT活性的化合物、含有该化合物的组合物以及治疗表达NAMPT的疾病的方法。本发明还涉及抑制ROCK活性的化合物、含有该化合物的组合物以及治疗表达ROCK的疾病的方法。